凝血酶与血凝酶,**不可以弄混!

2016-11-08 医学界临床药学频道 曹恩惠 医学界临床药学频道 曹恩惠

血凝酶是由巴西矛头蝮蛇(Bothrops Atrox)的蛇毒中分离提纯的。用于需减少流血或止血的医疗情况,可静脉注射、肌肉注射,也可局部使用。凝血酶为牛血或猪血中提取的凝血酶原,经激活而得的无菌冻干品。用于手术中不易结扎的小血管止血、消化道出血及外伤出血等。只能用于局部止血,口服或局部灌注,严禁注射,如误入血管可导致血栓形成、局部坏死危及生命。1、两者到底有多像?两者一般是单支发放。从外表上看两者

血凝酶是由巴西矛头蝮蛇(Bothrops Atrox)的蛇毒中分离提纯的。用于需减少流血或止血的医疗情况,可静脉注射、肌肉注射,也可局部使用。

凝血酶为牛血或猪血中提取的凝血酶原,经激活而得的无菌冻干品。用于手术中不易结扎的小血管止血、消化道出血及外伤出血等。只能用于局部止血,口服或局部灌注,严禁注射,如误入血管可导致血栓形成、局部坏死危及生命。



1、两者到底有多像?

两者一般是单支发放。从外表上看两者是这样的,名字极其相似,都为白色粉末,极易混淆。如错把凝血酶当血凝酶使用,注入血管,后果不堪设想可能危及生命!



2、如何来区分?

血凝酶和凝血酶,“血”在前面的,是能入“血”的,另一个严禁注射。如果发现处方或医嘱中凝血酶的使用方法为注射,必须拒绝发放,并告知医生更改处方。

另外,还有一些区别。比如血凝酶一般有“注射用”字样。有些品种的凝血酶外包装上有“严禁注射”的字样。

3、血凝酶和凝血酶资料汇总



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1954647, encodeId=c0b0195464e12, content=<a href='/topic/show?id=101988924c0' target=_blank style='color:#2F92EE;'>#血凝酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88924, encryptionId=101988924c0, topicName=血凝酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Apr 08 16:33:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154784, encodeId=d290154e847a, content=仔细的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff901728138, createdName=1dedfe95m66(暂无匿称), createdTime=Thu Nov 10 14:26:59 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154673, encodeId=71b31546e3fb, content=这有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161012/IMG57FE37B9D8B7C2781.jpg, createdBy=05f31956923, createdName=1e128d2fm65(暂无匿称), createdTime=Thu Nov 10 00:22:41 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154511, encodeId=1d19154511b3, content=非常好的帖子, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd7f1976397, createdName=1e171f9cm65(暂无匿称), createdTime=Wed Nov 09 08:24:45 CST 2016, time=2016-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154496, encodeId=bd0a154496c2, content=谢谢编辑。值得关注。看样子商品名的使用还是有必要。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01bb1684217, createdName=医张生, createdTime=Wed Nov 09 07:45:13 CST 2016, time=2016-11-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1954647, encodeId=c0b0195464e12, content=<a href='/topic/show?id=101988924c0' target=_blank style='color:#2F92EE;'>#血凝酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88924, encryptionId=101988924c0, topicName=血凝酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Apr 08 16:33:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154784, encodeId=d290154e847a, content=仔细的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff901728138, createdName=1dedfe95m66(暂无匿称), createdTime=Thu Nov 10 14:26:59 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154673, encodeId=71b31546e3fb, content=这有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161012/IMG57FE37B9D8B7C2781.jpg, createdBy=05f31956923, createdName=1e128d2fm65(暂无匿称), createdTime=Thu Nov 10 00:22:41 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154511, encodeId=1d19154511b3, content=非常好的帖子, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd7f1976397, createdName=1e171f9cm65(暂无匿称), createdTime=Wed Nov 09 08:24:45 CST 2016, time=2016-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154496, encodeId=bd0a154496c2, content=谢谢编辑。值得关注。看样子商品名的使用还是有必要。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01bb1684217, createdName=医张生, createdTime=Wed Nov 09 07:45:13 CST 2016, time=2016-11-09, status=1, ipAttribution=)]
    2016-11-10 1dedfe95m66(暂无匿称)

    仔细的文章

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1954647, encodeId=c0b0195464e12, content=<a href='/topic/show?id=101988924c0' target=_blank style='color:#2F92EE;'>#血凝酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88924, encryptionId=101988924c0, topicName=血凝酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Apr 08 16:33:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154784, encodeId=d290154e847a, content=仔细的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff901728138, createdName=1dedfe95m66(暂无匿称), createdTime=Thu Nov 10 14:26:59 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154673, encodeId=71b31546e3fb, content=这有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161012/IMG57FE37B9D8B7C2781.jpg, createdBy=05f31956923, createdName=1e128d2fm65(暂无匿称), createdTime=Thu Nov 10 00:22:41 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154511, encodeId=1d19154511b3, content=非常好的帖子, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd7f1976397, createdName=1e171f9cm65(暂无匿称), createdTime=Wed Nov 09 08:24:45 CST 2016, time=2016-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154496, encodeId=bd0a154496c2, content=谢谢编辑。值得关注。看样子商品名的使用还是有必要。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01bb1684217, createdName=医张生, createdTime=Wed Nov 09 07:45:13 CST 2016, time=2016-11-09, status=1, ipAttribution=)]
    2016-11-10 1e128d2fm65(暂无匿称)

    这有意思

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1954647, encodeId=c0b0195464e12, content=<a href='/topic/show?id=101988924c0' target=_blank style='color:#2F92EE;'>#血凝酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88924, encryptionId=101988924c0, topicName=血凝酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Apr 08 16:33:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154784, encodeId=d290154e847a, content=仔细的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff901728138, createdName=1dedfe95m66(暂无匿称), createdTime=Thu Nov 10 14:26:59 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154673, encodeId=71b31546e3fb, content=这有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161012/IMG57FE37B9D8B7C2781.jpg, createdBy=05f31956923, createdName=1e128d2fm65(暂无匿称), createdTime=Thu Nov 10 00:22:41 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154511, encodeId=1d19154511b3, content=非常好的帖子, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd7f1976397, createdName=1e171f9cm65(暂无匿称), createdTime=Wed Nov 09 08:24:45 CST 2016, time=2016-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154496, encodeId=bd0a154496c2, content=谢谢编辑。值得关注。看样子商品名的使用还是有必要。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01bb1684217, createdName=医张生, createdTime=Wed Nov 09 07:45:13 CST 2016, time=2016-11-09, status=1, ipAttribution=)]
    2016-11-09 1e171f9cm65(暂无匿称)

    非常好的帖子

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1954647, encodeId=c0b0195464e12, content=<a href='/topic/show?id=101988924c0' target=_blank style='color:#2F92EE;'>#血凝酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88924, encryptionId=101988924c0, topicName=血凝酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Apr 08 16:33:00 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154784, encodeId=d290154e847a, content=仔细的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff901728138, createdName=1dedfe95m66(暂无匿称), createdTime=Thu Nov 10 14:26:59 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154673, encodeId=71b31546e3fb, content=这有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161012/IMG57FE37B9D8B7C2781.jpg, createdBy=05f31956923, createdName=1e128d2fm65(暂无匿称), createdTime=Thu Nov 10 00:22:41 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154511, encodeId=1d19154511b3, content=非常好的帖子, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd7f1976397, createdName=1e171f9cm65(暂无匿称), createdTime=Wed Nov 09 08:24:45 CST 2016, time=2016-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154496, encodeId=bd0a154496c2, content=谢谢编辑。值得关注。看样子商品名的使用还是有必要。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01bb1684217, createdName=医张生, createdTime=Wed Nov 09 07:45:13 CST 2016, time=2016-11-09, status=1, ipAttribution=)]
    2016-11-09 医张生

    谢谢编辑。值得关注。看样子商品名的使用还是有必要。

    0

相关资讯

CCI:达比加群并不能减少STEMI后行直接PCI术患者的梗死面积

HIRIZON-AMI研究是一项大型、前瞻性、随机的急性心肌梗死患者接受再血管化治疗和支架的预后研究。在这项研究中比较了在ST段抬高性心肌梗死患者在直接PCI术后,使用直接凝血酶原抑制剂达比加群与普通肝素加糖蛋白IIb/IIIa受体拮抗剂对全因死亡率和心血管死亡的影响。由于减少大出血事件方面的效应,达比加群组的死亡率较低。但对STEMI患者而言,心肌梗死面积是除了大出血之外的一项影响预后的重要因素